AC
ARRY

Armistice Capital’s Array Biopharma Inc ARRY Stock Holding History

Armistice Capital’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,000,000
Closed -$5.9M – 54
2016
Q1 		$5.9M Buy
+2,000,000
New +$5.99M 2.32% 16

Other funds holding ARRY

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Armistice Capital's ARRY Position: Q2 2016 in Review

Armistice Capital sold out of Array Biopharma Inc (ARRY) in Q2 2016, closing a stake of 2,000,000 shares — an estimated $5.9M sold.

Armistice Capital first reported a position in ARRY in Q1 2016 and held it in 1 quarter. The position peaked at $5.9M in Q1 2016. 128 funds tracked by Wall St. Rank hold ARRY as of Q2 2016.

  • Armistice Capital reported no remaining Array Biopharma Inc position as of Q2 2016 after selling out during the quarter.
  • Armistice Capital sold 2,000,000 Array Biopharma Inc shares in Q2 2016, an estimated $5.9M.
  • Armistice Capital first reported a position in Array Biopharma Inc in Q1 2016 and held it in 1 quarter.
  • Armistice Capital's Array Biopharma Inc position peaked at $5.9M in Q1 2016.
  • 128 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2016.

Based on Armistice Capital's 13F filing for Q2 2016, filed 15 Aug 2016.